Trade Opiant Pharmaceuticals, Inc. - OPNT CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | N/A |
| Open* | 20.72 |
| 1-Year Change* | -20.22% |
| Day's Range* | 20.57 - 20.94 |
| 52 wk Range | 7.34-29.25 |
| Average Volume (10 days) | 90.34K |
| Average Volume (3 months) | 1.58M |
| Market Cap | 108.80M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 5.27M |
| Revenue | 22.34M |
| EPS | -6.56 |
| Dividend (Yield %) | N/A |
| Beta | 0.82 |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 1, 2023 | 20.60 | -0.11 | -0.53% | 20.71 | 20.94 | 20.52 |
| Feb 28, 2023 | 20.73 | 0.06 | 0.29% | 20.67 | 20.87 | 20.67 |
| Feb 27, 2023 | 20.73 | 0.06 | 0.29% | 20.67 | 20.83 | 20.67 |
| Feb 24, 2023 | 20.83 | 0.31 | 1.51% | 20.52 | 20.94 | 20.52 |
| Feb 23, 2023 | 20.71 | -0.08 | -0.38% | 20.79 | 20.85 | 20.52 |
| Feb 22, 2023 | 20.77 | 0.24 | 1.17% | 20.53 | 20.99 | 20.52 |
| Feb 21, 2023 | 20.73 | -0.22 | -1.05% | 20.95 | 20.96 | 20.54 |
| Feb 17, 2023 | 20.86 | 0.03 | 0.14% | 20.83 | 20.92 | 20.74 |
| Feb 16, 2023 | 20.81 | -0.16 | -0.76% | 20.97 | 21.17 | 20.78 |
| Feb 15, 2023 | 20.91 | 0.17 | 0.82% | 20.74 | 20.97 | 20.74 |
| Feb 14, 2023 | 20.94 | 0.12 | 0.58% | 20.82 | 21.05 | 20.74 |
| Feb 13, 2023 | 20.92 | 0.02 | 0.10% | 20.90 | 20.96 | 20.75 |
| Feb 10, 2023 | 21.06 | 0.23 | 1.10% | 20.83 | 21.09 | 20.73 |
| Feb 9, 2023 | 20.75 | -0.23 | -1.10% | 20.98 | 21.01 | 20.72 |
| Feb 8, 2023 | 21.07 | 0.33 | 1.59% | 20.74 | 21.11 | 20.55 |
| Feb 7, 2023 | 20.93 | 0.23 | 1.11% | 20.70 | 21.03 | 20.54 |
| Feb 6, 2023 | 20.77 | 0.25 | 1.22% | 20.52 | 21.07 | 20.47 |
| Feb 3, 2023 | 20.17 | 0.18 | 0.90% | 19.99 | 20.18 | 19.99 |
| Feb 2, 2023 | 20.07 | 0.08 | 0.40% | 19.99 | 20.07 | 19.96 |
| Feb 1, 2023 | 20.00 | -0.13 | -0.65% | 20.13 | 20.16 | 19.98 |
Opiant Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 47.7855 | 29.6252 | 40.5198 | 13.9822 | 11.7623 |
| Revenue | 47.7855 | 29.6252 | 40.5198 | 13.9822 | 11.7623 |
| Total Operating Expense | 42.6292 | 31.8662 | 29.5918 | 35.2226 | 10.2342 |
| Selling/General/Admin. Expenses, Total | 16.7292 | 16.4295 | 12.8087 | 25.2027 | 6.32576 |
| Research & Development | 16.8335 | 9.24002 | 9.07935 | 8.47882 | 2.48651 |
| Operating Income | 5.15631 | -2.24102 | 10.928 | -21.2404 | 1.52812 |
| Interest Income (Expense), Net Non-Operating | -2.12325 | -0.04611 | 0.48783 | 0.09639 | 0.02043 |
| Net Income Before Taxes | 3.03306 | -2.28713 | 11.4158 | -21.144 | 1.54854 |
| Net Income After Taxes | 3.00879 | -1.86145 | 11.5931 | -21.1953 | 1.37938 |
| Net Income Before Extra. Items | 3.00879 | -1.86145 | 11.5931 | -21.1953 | 1.37938 |
| Net Income | 3.00879 | -1.86145 | 11.5931 | -21.1953 | 1.37938 |
| Income Available to Common Excl. Extra. Items | 3.00879 | -1.86145 | 11.5931 | -21.1953 | 1.37938 |
| Income Available to Common Incl. Extra. Items | 3.00879 | -1.86145 | 11.5931 | -21.1953 | 1.37938 |
| Diluted Net Income | 3.00879 | -1.86145 | 11.5931 | -21.1953 | 1.37938 |
| Diluted Weighted Average Shares | 5.92007 | 4.24983 | 5.34238 | 2.98534 | 4.39314 |
| Diluted EPS Excluding Extraordinary Items | 0.50824 | -0.43801 | 2.17002 | -7.09981 | 0.31398 |
| Diluted Normalized EPS | 0.50824 | -0.43801 | 2.16801 | -7.08893 | 0.31681 |
| Cost of Revenue, Total | 9.06643 | 6.19671 | 7.72028 | 1.4911 | 1.40801 |
| Gross Profit | 38.7191 | 23.4285 | 32.7995 | 12.4911 | 10.3543 |
| Unusual Expense (Income) | 0 | -0.0165 | 0.04998 | 0.01392 | |
| Dividends per Share - Common Stock Primary Issue | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 4.47001 | 13.8002 | 16.3391 | 11.2593 | 6.38688 |
| Revenue | 4.47001 | 13.8002 | 16.3391 | 11.2593 | 6.38688 |
| Cost of Revenue, Total | 0.42626 | 2.92138 | 3.05887 | 2.10673 | 0.97947 |
| Gross Profit | 4.04375 | 10.8788 | 13.2802 | 9.15258 | 5.40741 |
| Total Operating Expense | 16.258 | 12.5262 | 12.3786 | 9.01278 | 8.71156 |
| Selling/General/Admin. Expenses, Total | 7.00854 | 4.89039 | 4.43836 | 3.75655 | 3.6439 |
| Research & Development | 8.82318 | 4.71445 | 4.8814 | 3.1495 | 4.08819 |
| Operating Income | -11.788 | 1.27401 | 3.96044 | 2.24653 | -2.32468 |
| Interest Income (Expense), Net Non-Operating | -0.39986 | -0.49741 | -0.54335 | -0.56294 | -0.51956 |
| Net Income Before Taxes | -12.1878 | 0.7766 | 3.4171 | 1.68359 | -2.84423 |
| Net Income After Taxes | -12.1878 | 0.75233 | 3.4171 | 1.68359 | -2.84423 |
| Net Income Before Extra. Items | -12.1878 | 0.75233 | 3.4171 | 1.68359 | -2.84423 |
| Net Income | -12.1878 | 0.75233 | 3.4171 | 1.68359 | -2.84423 |
| Income Available to Common Excl. Extra. Items | -12.1878 | 0.75233 | 3.4171 | 1.68359 | -2.84423 |
| Income Available to Common Incl. Extra. Items | -12.1878 | 0.75233 | 3.4171 | 1.68359 | -2.84423 |
| Diluted Net Income | -12.1878 | 0.75233 | 3.4171 | 1.68359 | -2.84423 |
| Diluted Weighted Average Shares | 5.01526 | 6.98508 | 6.06504 | 5.42783 | 4.28292 |
| Diluted EPS Excluding Extraordinary Items | -2.43015 | 0.10771 | 0.56341 | 0.31018 | -0.66409 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -2.43015 | 0.10771 | 0.56341 | 0.31018 | -0.66409 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 69.159 | 59.0992 | 39.2547 | 29.3706 | 20.7549 |
| Cash and Short Term Investments | 52.8687 | 48.2513 | 30.9805 | 24.6136 | 8.1159 |
| Cash & Equivalents | 37.854 | 48.2513 | 30.9805 | 24.6136 | 8.1159 |
| Total Receivables, Net | 13.3274 | 8.91098 | 7.21837 | 4.48932 | 11.6967 |
| Accounts Receivable - Trade, Net | 13.3274 | 8.91098 | 7.21837 | 4.48932 | 11.6967 |
| Prepaid Expenses | 2.9629 | 1.93684 | 1.05582 | 0.26762 | 0.73333 |
| Total Assets | 70.4278 | 60.613 | 40.2805 | 29.3863 | 20.7733 |
| Property/Plant/Equipment, Total - Net | 1.07767 | 0.44965 | 1.01148 | 0 | 0.00118 |
| Property/Plant/Equipment, Total - Gross | 0.00754 | ||||
| Accumulated Depreciation, Total | -0.00635 | ||||
| Intangibles, Net | 0.01163 | 0.013 | 0.01437 | 0.01575 | 0.01712 |
| Total Current Liabilities | 6.84556 | 6.42024 | 5.60982 | 9.82706 | 5.65719 |
| Payable/Accrued | 3.36985 | 2.96648 | 1.31677 | 1.13296 | 3.15699 |
| Accrued Expenses | 0.53894 | 1.19094 | 1.75459 | 1.08364 | 0.71349 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 2.93677 | 2.26283 | 2.53845 | 7.61045 | 1.78671 |
| Total Liabilities | 23.588 | 25.1208 | 5.86448 | 12.5271 | 7.773 |
| Total Long Term Debt | 16.0691 | 18.7006 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.67335 | 0 | 0.25466 | 2.7 | 2.11581 |
| Total Equity | 46.8398 | 35.4922 | 34.416 | 16.8593 | 13.0002 |
| Common Stock | 0.00491 | 0.00426 | 0.00419 | 0.00385 | 0.00254 |
| Additional Paid-In Capital | 108.57 | 100.204 | 97.2395 | 91.2761 | 66.2231 |
| Retained Earnings (Accumulated Deficit) | -61.6803 | -64.6891 | -62.8276 | -74.4207 | -53.2253 |
| Total Liabilities & Shareholders’ Equity | 70.4278 | 60.613 | 40.2805 | 29.3863 | 20.7733 |
| Total Common Shares Outstanding | 4.90985 | 4.25811 | 4.18644 | 3.84536 | 2.53577 |
| Other Current Assets, Total | 0 | 0.20904 | |||
| Other Long Term Assets, Total | 0.17953 | 1.05123 | |||
| Long Term Debt | 16.0691 | 18.7006 | |||
| Other Equity, Total | -0.05482 | -0.02693 | |||
| Short Term Investments | 15.0147 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 59.1599 | 69.159 | 67.8764 | 60.518 | 56.1037 |
| Cash and Short Term Investments | 50.8255 | 52.8687 | 50.3293 | 48.5156 | 48.048 |
| Cash & Equivalents | 48.3254 | 37.854 | 35.2846 | 33.4433 | 35.4496 |
| Short Term Investments | 2.50009 | 15.0147 | 15.0448 | 15.0723 | 12.5984 |
| Total Receivables, Net | 4.45339 | 13.3274 | 15.4259 | 9.72539 | 5.60902 |
| Accounts Receivable - Trade, Net | 4.45339 | 13.3274 | 15.4259 | 9.72539 | 5.60902 |
| Prepaid Expenses | 3.88101 | 2.9629 | 2.12115 | 2.277 | 2.44677 |
| Total Assets | 60.3188 | 70.4278 | 68.9797 | 61.7584 | 58.9033 |
| Property/Plant/Equipment, Total - Net | 0.94517 | 1.07767 | 1.0913 | 1.22806 | 0.28621 |
| Intangibles, Net | 0.01129 | 0.01163 | 0.01197 | 0.01231 | 0.01266 |
| Long Term Investments | 2.50068 | ||||
| Other Long Term Assets, Total | 0.20242 | 0.17953 | 0 | 0 | |
| Total Current Liabilities | 6.78761 | 6.84556 | 7.35227 | 5.78407 | 6.1486 |
| Payable/Accrued | 5.31865 | 3.36985 | 2.5809 | 2.44698 | 3.68024 |
| Accrued Expenses | 1.04271 | 0.53894 | 1.63469 | 1.23022 | 0.62955 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.42626 | 2.93677 | 3.13668 | 2.10686 | 1.8388 |
| Total Liabilities | 21.0556 | 23.588 | 26.9743 | 25.4023 | 24.9175 |
| Total Long Term Debt | 13.66 | 16.0691 | 18.9057 | 18.8373 | 18.7689 |
| Long Term Debt | 13.66 | 16.0691 | 18.9057 | 18.8373 | 18.7689 |
| Total Equity | 39.2632 | 46.8398 | 42.0054 | 36.3561 | 33.9857 |
| Common Stock | 0.00508 | 0.00491 | 0.00462 | 0.00435 | 0.00433 |
| Additional Paid-In Capital | 113.208 | 108.57 | 104.46 | 102.22 | 101.529 |
| Retained Earnings (Accumulated Deficit) | -73.8681 | -61.6803 | -62.4326 | -65.8497 | -67.5333 |
| Other Equity, Total | -0.08197 | -0.05482 | -0.02685 | -0.01888 | -0.01443 |
| Total Liabilities & Shareholders’ Equity | 60.3188 | 70.4278 | 68.9797 | 61.7584 | 58.9033 |
| Total Common Shares Outstanding | 5.07961 | 4.90985 | 4.61822 | 4.3496 | 4.33059 |
| Other Liabilities, Total | 0.60802 | 0.67335 | 0.71634 | 0.7809 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 3.00879 | -1.86145 | 11.5931 | -21.1953 | 1.37938 |
| Cash From Operating Activities | 1.92649 | -2.02877 | 4.06389 | -0.52297 | -3.84049 |
| Amortization | 0.00256 | 0.00214 | |||
| Non-Cash Items | 3.58334 | 2.78078 | 3.35786 | 6.54266 | 1.79359 |
| Cash Interest Paid | 1.53562 | 0 | 0 | ||
| Changes in Working Capital | -4.76009 | -3.07178 | -10.9478 | 14.1271 | -7.0156 |
| Cash From Investing Activities | -15.0147 | -0.05089 | -0.30248 | 0 | |
| Capital Expenditures | 0 | -0.05089 | -0.30248 | 0 | |
| Cash From Financing Activities | 2.71894 | 19.3692 | 2.60542 | 17.0207 | 5.08383 |
| Financing Cash Flow Items | 0 | -1.31594 | -0.07 | -0.16642 | -0.20904 |
| Issuance (Retirement) of Debt, Net | 0 | 20 | 0 | 0 | |
| Net Change in Cash | -10.3974 | 17.2709 | 6.36684 | 16.4977 | 1.24335 |
| Cash Taxes Paid | 0 | 0.039 | 0.0008 | 0.174 | 0.61923 |
| Issuance (Retirement) of Stock, Net | 2.71894 | 0.6851 | 2.67542 | 17.1871 | 5.29288 |
| Cash From Operating Activities | 0.09446 | 0.12368 | 0.06081 | ||
| Foreign Exchange Effects | -0.02807 | -0.01864 | |||
| Other Investing Cash Flow Items, Total | -15.0147 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -12.1878 | 3.00879 | 2.25646 | -1.16064 | -2.84423 |
| Cash From Operating Activities | -2.10326 | 1.92649 | -0.07706 | -0.36345 | 1.7125 |
| Cash From Operating Activities | 0.0079 | 0.09446 | 0.0787 | 0.06295 | 0.03147 |
| Non-Cash Items | 2.23628 | 3.58334 | 2.68829 | 1.82681 | 0.94172 |
| Cash Interest Paid | 0.41496 | 1.53562 | 1.05151 | 0.58301 | 0.11452 |
| Changes in Working Capital | 7.84039 | -4.76009 | -5.10052 | -1.09256 | 3.58353 |
| Cash From Investing Activities | 12.5147 | -15.0147 | -15.0448 | -15.0723 | -15.1088 |
| Other Investing Cash Flow Items, Total | 12.5147 | -15.0147 | -15.0448 | -15.0723 | -15.1088 |
| Cash From Financing Activities | 0.09746 | 2.71894 | 2.16206 | 0.61622 | 0.57962 |
| Issuance (Retirement) of Stock, Net | 0.09163 | 2.71894 | 2.16206 | 0.61622 | 0.57962 |
| Foreign Exchange Effects | -0.03737 | -0.02807 | -0.00699 | 0.01149 | 0.01489 |
| Net Change in Cash | 10.4715 | -10.3974 | -12.9667 | -14.8081 | -12.8018 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | |||
| Financing Cash Flow Items | 0.00582 | 0 | |||
| Issuance (Retirement) of Debt, Net | 0 |
Opiant Pharmaceuticals, Inc. Company profile
About Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company’s pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Opiant Pharmaceuticals Inc revenues increased 61% to $47.8M. Net income totaled $3M vs. loss of $1.9M. Revenues reflect Royalty revenue increase of 49% to $40.7M, Grant and contract revenue increase from $2.2M to $7.1M. Net Income reflects Sales and marketing decrease of 2% to $4.6M (expense), Gain (loss) on foreign exchange decrease of 44% to $5K (expense).
Equity composition
Common Stock $.001 Par, 10/11, 200M auth., 91,996,333 issd. Insiders own 21.97%. 08/09, 20-for-1 stocksplit. 8/09, Name changed from Madrona Ventures, Inc. 12/14, 1-for-100 reverse stock split.
| Industry: | Bio Therapeutic Drugs |
233 Wilshire Blvd
Suite 400
SANTA MONICA
CALIFORNIA 90401
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com